Differential Regulation of Peripheral Leukocyte Genes in Patients With Active Crohn's Disease and Crohn's Disease in Remission

Burakoff, Robert; Hande, Scott A.; Jun, Ma; Banks, Peter A.; Friedman, Sonia; Makrauer, Frederick L.; Liew, Choong‐Chin

doi:10.1097/mcg.0b013e3181a9ef53

Cited by 17 publications

(11 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…53,54 Among patients with IBD, gene expression profiles obtained from whole blood have been utilized to differentiate active from inactive CD. 55 Additionally, gene expression profiles have demonstrated the ability to differentiate between CD, UC, and other non-inflammatory diarrheal conditions. 56 More recently, the Affymetrix GeneChip technology was utilized to generate genome-wide expression profiles to predict disease activity in patients with UC and CD.…”

Section: New Approaches To Biomarkersmentioning

confidence: 99%

New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes

Barnes

Burakoff²

2016

Inflammatory Bowel Diseases

Self Cite

View full text Add to dashboard Cite

Despite advances in our understanding of the pathophysiology underlying Inflammatory Bowel Disease (IBD), there remains a significant need for biomarkers that can differentiate between Crohn's Disease (CD) and Ulcerative Colitis (UC) with high sensitivity and specificity, in a cost-efficient manner. As the focus on personalized approaches to the delivery of medical treatment increases, new biomarkers are being developed to predict an individual's response to therapy as well as their overall disease course. In this review, we will outline many of the existing and recently developed biomarkers, detailing their role in the assessment of patients with IBD. We will identify opportunities for improvement in our biomarkers, including better differentiation between the subtypes of IBD. We will also discuss new targets and strategies in biomarker development, including combining modalities to create biomarker signatures to improve the ability to predict disease courses and response to therapy among individual patients.

show abstract

Section: New Approaches To Biomarkersmentioning

confidence: 99%

New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes

Barnes

Burakoff²

2016

Inflammatory Bowel Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

“…Gene expression profiling in blood is a valuable method for identifying patterns of gene expression related to specific pathologic entities. A series of studies has shown that RNA expression profiles generated from circulating blood can be used to identify patients with a number of conditions, including lung cancer,1 bladder cancer,2 osteoarthritis,3 schizophrenia and bipolar disorder,4, 5 kidney diseases,6, 7 cardiovascular diseases,8–10 Crohn's disease (CD),11 and diabetes 12. Recently, gene expression profiling in blood has also been shown to have utility in distinguishing patients with or without colon cancer 13…”

mentioning

confidence: 99%

Blood-based biomarkers can differentiate ulcerative colitis from crohnʼs disease and noninflammatory diarrhea

Burakoff

Chao²,

Perencevich

et al. 2011

Inflammatory Bowel Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

“…In several studies we have shown that gene signatures obtained using blood mRNA can identify a variety of conditions occurring in various sites throughout the body, including heart failure [12], inflammatory bowel disease [13,14], psychiatric disorders [15-17] and various cancers [10,18-20]. These studies suggest that blood cells may act as “sentinels” that can mirror health or disease anywhere in the body.…”

Section: Discussionmentioning

confidence: 99%

Blood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case-control study

Chao¹,

Ying²,

Liew³

et al. 2013

J Exp Clin Cancer Res

Self Cite

View full text Add to dashboard Cite

BackgroundColonoscopy is widely regarded to be the gold standard for colorectal cancer (CRC) detection. Recent studies, however, suggest that the effectiveness of colonoscopy is mostly confined to tumors on the left side of the colon (descending, sigmoid, rectum), and that the technology has poor tumor detection for right-sided (cecum, ascending, transverse) lesions. A minimally invasive test that can detect both left-sided and right-sided lesions could increase the effectiveness of screening colonoscopy by revealing the potential presence of neoplasms in the right-sided “blind spot”.MethodsWe previously reported on a seven-gene, blood-based biomarker panel that effectively stratifies a patient’s risk of having CRC. For the current study, we assessed the effectiveness of the seven-gene panel for the detection of left- and right-sided CRC lesions. Results were evaluated for 314 patients with CRC (left-sided: TNM I, 65; TNM II, 57; TNM III, 60; TNM IV, 17; unknown, 9. right-sided: TNM I, 28; TNM II, 29; TNM III, 38; TNM IV, 12; unknown, 1 and including two samples with both left and right lesions) and 328 control samples. Blood samples were obtained prior to clinical staging and therapy. Most CRC subjects had localized disease (stages I and II, 58%); regional (stage III) and systemic (stage IV) disease represented 32% and 9%, respectively, of the study population.ResultsThe panel detected left-sided (74%, 154/208) and right-sided (85%, 92/108) lesions with an overall sensitivity of 78% (215/316) at a specificity of 66% (215/328). Treatable cancer (stages I to III) was detected with left-sided lesion sensitivity of 76% (138/182) and right-sided sensitivity of 84% (80/95).ConclusionThis seven-gene biomarker panel detected right-sided CRC lesions across all cancer stages with a sensitivity that is at least equal to that for left-sided lesions. This study supports the use of this panel as the basis for a patient-friendly, blood-based test that can be easily incorporated into a routine physical examination in advance of colonoscopy to provide a convenient companion diagnostic and a pre-screening alert, ultimately leading to enhanced CRC screening effectiveness.

show abstract

Differential Regulation of Peripheral Leukocyte Genes in Patients With Active Crohn's Disease and Crohn's Disease in Remission

Abstract: The genes differentially regulated in peripheral leukocytes represent potential new biomarkers for assessing the activity of Crohn's disease.

Cited by 17 publications

References 30 publications

New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes

New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes

Blood-based biomarkers can differentiate ulcerative colitis from crohnʼs disease and noninflammatory diarrhea

Blood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case-control study

Contact Info

Product

Resources

About